RIBOMIC Inc. announced that the first dose of RBM-007 (anti-FGF2 aptamer) was administered to a pediatric patient with Achondroplasia in the early phase II study to investigate the efficacy and safety of RBM-007. RBM-007 is a novel nucleic acid medicine (oligonucleotide-based aptamer) developed in-house at RIBOMIC's research facilities in Tokyo. RBM-007 has been shown to have potent effects in limiting excessive interactions between fibroblast growth factors, which are known to cause achondroplasia.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
90 JPY | 0.00% |
|
-8.16% | -16.67% |
1st Jan change | Capi. | |
---|---|---|
-16.67% | 20.8M | |
+20.12% | 126B | |
+25.25% | 119B | |
+25.56% | 27.95B | |
-19.51% | 20.5B | |
-14.36% | 17.12B | |
-15.63% | 16.1B | |
-46.67% | 14.97B | |
+11.89% | 14.84B | |
+57.74% | 14.38B |
- Stock Market
- Equities
- 4591 Stock
- News Ribomic Inc.
- RIBOMIC, Inc. Announces Start of Administration of RBM-007, Achondroplasia Investigational Drug, to the First Patient in the Early Phase II Study in Japan